| VIA Pharmaceuticals announced that on September 23, it received a deficiency letter from The NASDAQ Stock Market notifying the company of its failure to regain compliance with the board independence requirements, as set forth in Listing Rules 5605(b)(1) and 5605(c)(2)(A), and that the company's securities are, therefore, subject to delisting from The NASDAQ Capital Market. :theflyonthewall.com |
